The Use of Zoledronic Acid to Complex Regional Pain Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy and the safety of using a single, intravenous 5mg dose of zoledronic acid in managing pain in Complex Regional Pain Syndrome patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

NCT03560986

Complex Regional Pain Syndrome (CRPS)

TERMINATED PHASE3

Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain.

NCT02100046

Neuropathic Traumatic Pain Pain NRS ≥ 4 Peripheral Neuropathic Pain +1 more

COMPLETED PHASE2

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

NCT03530345

Complex Regional Pain Syndrome (CRPS)

TERMINATED PHASE3

Safety of Intravenous Neridronic Acid in CRPS

NCT02972359

Complex Regional Pain Syndrome

COMPLETED PHASE3

Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I

NCT02402530

Complex Regional Pain Syndrome, Type I

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Complex regional pain syndrome (CRPS) is a disorder of the extremities that is characterized by spontaneous unexplained disproportionate pain, hyperalgesia, swelling, limited range of motion, vasomotor instability, skin changes, and patchy bone demineralization.The incidence of CRPS was estimated to be 5.46 per 100,000 person years at risk in Olmsted County, Minnesota (US), with a prevalence of 20.57 per 100,000, while its incidence in the general population of the Netherlands was estimated to be much higher, at 26.2 per 100,000 person-years. The adverse effects were not serious and lasted just a few days. The beneficial effects of other bisphosphonates have been already documented in several placebo-controlled trials; however, there are no reports on the use of zoledronic acid to reduce pain in CRPS patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complex Regional Pain Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Saline

One single intravenous infusion of 100ml of saline (placebo control group).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

one single intravenous infusion of 100ml of saline.

Zoledronic acid

one single dose of 5mg intravenous infusion of zoledronic acid (interventional group)

Group Type ACTIVE_COMPARATOR

Zoledronic acid

Intervention Type DRUG

One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zoledronic acid

One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)

Intervention Type DRUG

Placebo

one single intravenous infusion of 100ml of saline.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients over 18 years of age of both genders, with continuing pain that is disproportionate to any inciting event, with cardinal features of CRPS.
2. Pain - after initial injury with signs and symptoms present at first visit
3. History of previous unsuccessful treatment for pain, with a minimum of two drug therapies, such as non steroidal anti-inflammatory drugs, steroids, antidepressants, central acting analgesics, calcitonin or sympathetic blocks, (not bisphosphonates) for at least six months.
4. Must report at least one symptom in three of the four following categories:

1. Sensory: Reports of hyperesthesia and/or allodynia
2. Vasomotor: Reports of temperature asymmetry and/or skin color changes and/or skin color asymmetry
3. Sudomotor/Edema: Reports of edema and/or sweating changes and/or sweating asymmetry
4. Motor/Trophic: Reports of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin).
5. Must display at least one sign\* at time of evaluation in two or more of the following categories:

1. Sensory: Evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch and/or deep somatic pressure and/or joint movement)
2. Vasomotor: Evidence of temperature asymmetry and/or skin color changes and/or asymmetry
3. Sudomotor/Edema: Evidence of edema and/or sweating changes and/or sweating asymmetry
4. Motor/Trophic: Evidence of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin).
6. Skin temperature of the affected side equal or higher than on the non-affected side.
7. No other diagnosis better explains the signs and symptoms.

Exclusion Criteria

1. Presence of systemic diseases including diabetes mellitus, hyperthyroidism, renal and liver dysfunction, peripheral vascular or cardiovascular diseases, uncontrolled hypertension, rheumatoid and hematopoietic diseases, neurological diseases not related to CRPS, overt alcohol addiction, positive pregnancy test and/or lactating women, hyperparathyroidism, and hypocalcaemia.
2. Creatinine clearance \<35mL/min, with serum creatinine measured before the dose of zoledronic acid.
3. Pre-existing hypocalcaemia and disturbance of mineral metabolism (e.g. hyperparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, and excision of small intestine).
4. Hypersensitivity to zoledronic acid or any component drugs used in the trial.
5. Patients with asthma and aspirin-sensitivity
6. Pregnancy or unwillingness to use contraceptive methods during the trial
7. Patients who have previously used any kind of bisphosphonate, especially zoledronic acid.
8. Osteoporosis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No